Does Rallies show 13F holders for NVCT?

Yes. Rallies tracks hedge fund and 13F ownership data for NVCT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is NVCT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NVCT. It does not provide personalized investment advice.

NVCT (Nuvectis Pharma, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Nuvectis Pharma, Inc. Common Stock (NVCT) is a publicly traded Healthcare sector company. As of May 21, 2026, NVCT trades at $10.63 with a market cap of $275.87M and a P/E ratio of -7.99. NVCT moved +3.11% today. Year to date, NVCT is +24.62%; over the trailing twelve months it is -0.19%. Its 52-week range spans $4.44 to $13.34. Analyst consensus is buy with an average price target of $13.50. Rallies surfaces NVCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns NVCT stock?

Hedge funds tracked by Rallies that own NVCT include Two Sigma and Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Nuvectis Pharma, Inc. Common Stock.

NVCT Key Metrics

Key financial metrics for NVCT
Metric	Value
Price	$10.63
Market Cap	$275.87M
P/E Ratio	-7.99
EPS	$-1.32
Dividend Yield	0.00%
52-Week High	$13.34
52-Week Low	$4.44
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-26.44M
Gross Margin	0.00%

Top Hedge Funds Holding NVCT

Two Sigma holds 18.57K shares of NVCT, changed -30.67% as of Dec 31, 2024.
Renaissance Technologies holds 15.80K shares of NVCT, changed -78.79% as of Sep 30, 2024.

Latest NVCT News

Nuvectis Pharma Q1 Cash Falls to $25.1M, Net Loss Widens to $6.1M — May 5, 2026
Nuvectis to Present NXP900 Synergy and Resistance Data at AACR April 21–22 — Mar 31, 2026
Nuvectis Raises Cash to $31.6M, Reports $26.4M Net Loss and Phase 1b Progress — Feb 11, 2026

Recent NVCT Insider Trades

BENTSUR RON bought 5.00K (~$28.60K) on Nov 5, 2025.
Sanchez Juan bought 13.00K (~$75.27K) on Nov 5, 2025.
Kaplan Matthew L. bought 11.00K (~$64.24K) on Nov 5, 2025.

NVCT Analyst Consensus

2 analysts cover NVCT: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $13.50.

Common questions about NVCT

Who owns NVCT stock?: Hedge funds tracked by Rallies that own NVCT include Two Sigma and Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Nuvectis Pharma, Inc. Common Stock.
Does Rallies show 13F holders for NVCT?: Yes. Rallies tracks hedge fund and 13F ownership data for NVCT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NVCT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NVCT. It does not provide personalized investment advice.